News


  • 05 January 2017

    Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

    Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and  Trademark Office for U.S. Patent Application Number  15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”

  • 05 January 2017

    Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

    Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors.

  • 04 January 2017

    Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

    Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of  Richard L. Beckman , M.D. to the position of Chief Medical Officer.

  • 03 January 2017

    Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

    Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).

  • 28 December 2016

    Happy New Year!

    Happy New Year!

    Merry Christmas and a prosperous New Year!  Best wishes for 2017!

    RMI Partners team wishes you Happy Holidays! May all your endeavors and met with huge success and appreciation! Harmony and joy to you and your loved ones!

  • 23 December 2016

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

  • 23 December 2016

    Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

    Neothetics, Inc.  (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of submental subcutaneous fat.

  • 19 December 2016

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    The Expert Opinion. Maxim Gorbachev: "2016 Was a Good Year for Our Venture Biotech Portfolio - 2 IPO and 2 Acquisitions"

    Maxim Gorbachev, Managing Partner: "It’s right time to make the first results of 2016. Let’s have a quick look back on venture biotech market in 2016. How 2016 was for RMI Partners? On the contrary, we have a good year. Two of our portfolio companies have made IPO despite unfavorable market conditions and two - have been acquired at pretty nice valuations."

  • 14 December 2016

    Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

    Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

    Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for intramural preclinical and clinical research.

  • 14 December 2016

    Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

    Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

    Сlearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NBI will become effective at market open on  Monday, December 19, 2016 .